Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
How Information is Consumed
Summary
In this episode, Tom Caravela is joined by Andrew Fariello from AstraZeneca to explore the evolving landscape of Medical Science Liaisons (MSLs) in the context of data sharing and technological advancements. Andrew shares his career journey and insights into the growing importance of surveillance networks and real-world data, especially following the pandemic. The discussion delves into adapting MSL strategies to handle information overload while integrating patient perspectives into medical strategies. Andrew emphasizes the critical role of MSLs, highlighting advancements in engagement and innovative tools. The episode concludes with advice for MSLs navigating scientific developments and a call to action for listeners.
Today’s guest is Andrew Fariello, VP Global Medical Affairs, Head Medical Excellence, Oncology who discusses trends in information/data consumption and what MSLs can do for greater impact
We learn….
👉 How data is being shared as well as how it is being consumed
👉 What he means by the term “instantaneous Information”
👉 What role MSLs play in patient care and patient identification
👉 How the MSL approach may need to change
👉 Areas of improvement for MSLs in KOL engagement
Medical Science Liaisons, Andrew Fariello, AstraZeneca, data sharing, technological advancements
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO